Deendyal Bhurta

发表

Evaluation of rohitukine-enriched fraction of Dysoxylum binectariferum Hook.f. (leaves) as anti-arthritic phytopharmaceutical candidate: Chemical standardization, in-vivo validation, formulation development and oral pharmacokinetics.

Ajay Kumar, S. Bharate, Sonali S. Bharate, 2020, Journal of ethnopharmacology.

Cell-intrinsic Aryl Hydrocarbon Receptor signalling is required for the resolution of injury-induced colonic stem cells

M. Llorian, B. Stockinger, P. Chakravarty, 2021, Nature Communications.

The medicinal perspective of 2,4‐thiazolidinediones based ligands as antimicrobial, antitumor and antidiabetic agents: A review

Vikramdeep Monga, Deendyal Bhurta, Gurpreet Singh, 2022, Archiv der Pharmazie.

A rohitukine derivative IIIM‐290 induces p53 dependent mitochondrial apoptosis in acute lymphoblastic leukemia cells

D. Mondhe, F. Malik, S. Bharate, 2021, Molecular carcinogenesis.

Discovery of Pongol, the Furanoflavonoid, as an Inhibitor of CDK7/Cyclin H/MAT1 and Its Preliminary Structure–Activity Relationship

S. Bharate, Deendyal Bhurta, 2022, ACS omega.

Analyzing the scaffold diversity of cyclin‐dependent kinase inhibitors and revisiting the clinical and preclinical pipeline

S. Bharate, Deendyal Bhurta, 2021, Medicinal research reviews.

Orally bioavailable styryl derivative of rohitukine-N-oxide inhibits CDK9/T1 and the growth of pancreatic cancer cells.

S. Bharate, Deendyal Bhurta, Utpal Nandi, 2023, European journal of medicinal chemistry.

Impurity profiling of anticancer preclinical candidate, IIIM‐290

Prof Vikas Kumar, S. Bharate, Sonali S. Bharate, 2019, Journal of pharmaceutical and biomedical analysis.

Design, synthesis, biological evaluation and molecular modelling studies of novel diaryl substituted pyrazolyl thiazolidinediones as potent pancreatic lipase inhibitors.

Vikramdeep Monga, Deendyal Bhurta, Ginson George, 2017, Bioorganic & medicinal chemistry letters.

Styryl Group, a Friend or Foe in Medicinal Chemistry

S. Bharate, Deendyal Bhurta, 2022, ChemMedChem.